Cargando…
Effective low–dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach–Merritt phenomenon in young infants
AIMS: Management of kaposiform haemangioendotheliomas (KHE) with Kasabach–Merritt phenomenon is challenging in young infants who are subjected to developmental pharmacokinetic changes. Sirolimus, sometimes combined with corticosteroids, can be used as an effective treatment of KHE. Simultaneously, t...
Autores principales: | Harbers, Veroniek E. M., van der Salm, Nathalie, Pegge, Sjoert A. H., van der Vleuten, Carine J. M., Verhoeven, Bas H., Vrancken, Sabine L. A. G., Schultze Kool, Leo J., Fuijkschot, Joris, te Loo, D. Maroeska M. W. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303919/ https://www.ncbi.nlm.nih.gov/pubmed/34957601 http://dx.doi.org/10.1111/bcp.15202 |
Ejemplares similares
-
Kaposiform haemangioendothelioma with Kasabach - Merritt phenomenon
por: Jandial, Aditya, et al.
Publicado: (2020) -
Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon
por: Alaqeel, Alaa M., et al.
Publicado: (2016) -
Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate
por: Cabrera, Trevor B., et al.
Publicado: (2020) -
Local suture ligation-assisted percutaneous sclerotherapy for Kasabach-Merritt phenomenon-associated kaposiform haemangioendothelioma
por: Li, Xiao, et al.
Publicado: (2019) -
Kaposiform hemangioendothelioma with fatal income: Kasabach–Merritt phenomenon and hypercalcemia
por: Massara, Baklouti, et al.
Publicado: (2022)